Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
Preliminary Results From a Randomized, Open-Label, Phase 2 Study of Botensilimab With or Without Balstilimab in Refractory Microsatellite Stable Metastatic Colorectal Cancer With No Liver Metastases
Fakih, et al.
Filter by
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 6
- Nov 10, 2024
Fc-Enhanced Anti-CTLA-4 Antibody, Botensilimab, Enhances the Efficacy of Multiple Therapeutic Modalities in Immunotherapy-Refractory Tumor Models
Levey, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Nature Medicine
Sep 30, 2024
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology
Sep 13
- Sep 17, 2024
Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study
Wilky, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 26
- Jun 29, 2024
Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer
Kasi, et. al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society of Clinical Oncology (ASCO)
May 31
- Jun 4, 2024
Botensilimab (BOT) plus balstilimab (BAL) in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites
Fakih, et al.
AGEN1777
American Association of Cancer Research (AACR)
Apr 5
- Apr 10, 2024
BMS-986442 (AGEN1777), a novel TIGIT/CD96 bispecific antibody, demonstrates superior monotherapy and combination activity versus conventional anti-TIGIT antibodies in preclinical models
Chand, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 18
- Jan 20, 2024
Neoadjuvant botensilimab plus balstilimab (BOT/BAL) in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial.
Kasi, et. al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Oncoimmunology
Nov 5, 2023
Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO)
Oct 21, 2023
Efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma
Wilky, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Connective Tissue Oncology Society (CTOS)
Oct 13, 2023
Efficacy and safety of Botensilimab plus Balstilimab combination therapy in refractory metastatic sarcoma patients: findings from an ongoing expanded phase 1b study
Wilky, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Oncogene
Sep 21, 2023
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 28
- Jul 1, 2023
Results from an expanded phase 1 trial of botensilimab, a multifunctional anti-CTLA-4, plus balstilimab(anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
Bullock, et al.